( American Society of Hematology ) The promising investigational targeted therapy ibrutinib and its mechanism of silencing gene communication pathways critical to the development of cancer may be an effective way to combat chronic lymphocytic leukemia, according to studies presented today at the 54th Annual Meeting of the American Society of Hematology.

See the rest here:

Investigational agent targets gene signaling pathways to improve response for patients with CLL